Alexion Pharmaceuticals, Inc.
ALXNDelisted Jul 21, 2021- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000899866
Alexion Pharmaceuticals, Inc. was delisted on Jul 21, 2021; its insiders filed their last Form 4 on Jul 23, 2021; 711 institutions reported holding it in 13F filings for Q2 2021, worth $39.1B in total; superinvestors Soros Fund Management and Maverick Capital held it.
13F holders, Q2 2021
Institutional positions in Alexion Pharmaceuticals, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
ALXN is no longer listed, so this page shows Q2 2021. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 711
- −35 vs. Q1 2021
- Shares held
- 212.2M
- +9.05M (+4.5%) vs. Q1 2021
- Total value
- $39.1B
- +$8.00B (+25.8%) vs. Q1 2021
- New holders
- 67
- 241 more added
- Sold out
- 102
- 297 more reduced
9 institutions that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALXN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 2 | $2.16M |
| Q4 2025 | 1 | $5.40K |
| Q3 2025 | 1 | $5.79K |
| Q2 2025 | 1 | $5.52K |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $924.0K |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 1 | $8.83K |
| Q3 2023 | 1 | $10.4K |
| Q2 2023 | 1 | $13.6K |
| Q1 2023 | 1 | $13.0K |
| Q4 2022 | 1 | $13.0K |
| Q3 2022 | 1 | $16.0K |
| Q2 2022 | 1 | $13.0K |
| Q1 2022 | 1 | $13.0K |
| Q4 2021 | 2 | $14.0K |
| Q3 2021 | 7 | $823.0K |
| Q2 2021 | 711 | $39.1B |
| Q1 2021 | 755 | $31.3B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Alexion Pharmaceuticals, Inc.; share changes are against Q1 2021.